Fetal bovine serum (FBS), also known as fetal calf serum, is a vital component in cell culture for research and biopharmaceutical production. FBS is derived from the blood of fetal cows and is rich in growth factors and other nutrients that support cell growth and proliferation. The global fetal bovine serum market has been growing steadily over the years, driven by the increasing demand for cell culture-based research and development activities in the biopharmaceutical industry. The fetal bovine serum market was estimated at US$ 874.1 million in 2021 and is expected to grow at a CAGR of 5.18% during 2022-2028 to reach US$ ~1.19 billion in 2028.

The FBS market is segmented by type, application, and geography. By type, the market is categorized into North America-sourced, South America-sourced, Australia-sourced, and others. North America and Australia are the largest sources of FBS, with the former accounting for the majority of the market share. South America-sourced FBS is also gaining popularity due to its lower price compared to North America-sourced FBS.

Request a sample here:

https://www.stratviewresearch.com/Request-Sample/3158/fetal-bovine-serum-market.html#form

Based on application, the FBS market is segmented into biopharmaceutical production, academic research, and others. Biopharmaceutical production is the largest application segment, accounting for more than half of the market share. The increasing demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and cell therapies, is driving the demand for FBS in this segment.

North America and Europe are currently the two major markets for foetal bovine serum, and they are likely to account for a higher share of the market during the forecast period. This is because these regions have large populations of bovine and cattle to permit the production of foetal bovine serum, as well as a high share of RD activities. Because of its vast cattle population and favourable government backing for research and development, Australia is likely to present the largest market opportunity in Asia Pacific.

The FBS market is highly competitive, with a large number of players operating globally. The state of the economy and government assistance have a direct impact on the expansion of the businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their fetal bovine serum driver in the industry. Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:

• In July 2017, GE Healthcare and Oritain revealed the debut of a serum fraud testing service.
• Nucleus Biologics introduced the first premium foetal bovine serum in January 2017 to enable scientific advances while RD projects are underway.

The overall competitive landscape has been affected due to the key strategic activities. The following are the major players in the fetal bovine serum market:

• HiMedia Laboratories
• Merck KGaA
• Bovogen Biologicals Pty Ltd
• Atlanta Biologicals Inc.
• TCS Biosciences Ltd
• Tissue Culture Biologicals
• Rocky Mountain Biologicals
• GE Healthcare
• Thermo Fisher Scientific
• Bio-Techne
• PAN-Biotech
• Access Biologicals

However, the FBS market is facing several challenges that may hinder its growth in the future. One of the major challenges is the ethical concerns associated with the use of FBS. The collection of FBS involves the slaughter of pregnant cows, which has raised ethical concerns among animal welfare activists. Moreover, the supply of FBS is limited and subject to fluctuations, which can lead to price volatility and supply chain disruptions.

To overcome these challenges, the industry is exploring alternative sources of serum-free media, such as plant-based and synthetic media. These alternatives offer several advantages over FBS, including better consistency, lower cost, and reduced risk of contamination. However, the adoption of these alternatives is still in its early stages, and FBS is expected to remain the dominant cell culture supplement for the foreseeable future.

In conclusion, the global fetal bovine serum market is expected to continue its growth trajectory in the coming years, driven by the increasing demand for cell culture-based research and biopharmaceutical production. However, the industry must address the ethical concerns and supply chain challenges associated with FBS to ensure sustainable growth in the future.